PMC:7309518 / 14846-15137 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T100","span":{"begin":76,"end":88},"obj":"Body_part"},{"id":"T101","span":{"begin":112,"end":117},"obj":"Body_part"}],"attributes":[{"id":"A100","pred":"fma_id","subj":"T100","obj":"http://purl.org/sig/ont/fma/fma82816"},{"id":"A101","pred":"fma_id","subj":"T101","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"s and, in the presence of chloroquine, the SARS-CoV viral spike cannot bind gangliosides to infect the targeted cells.15 If benefit is confirmed and safety is established, chloroquine may be of added therapeutic value in future patients with COVID-19–triggered GBS in conjunction with IVIg.\n"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T213","span":{"begin":43,"end":51},"obj":"Disease"},{"id":"T214","span":{"begin":242,"end":250},"obj":"Disease"},{"id":"T215","span":{"begin":261,"end":264},"obj":"Disease"}],"attributes":[{"id":"A213","pred":"mondo_id","subj":"T213","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A214","pred":"mondo_id","subj":"T214","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A215","pred":"mondo_id","subj":"T215","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"}],"text":"s and, in the presence of chloroquine, the SARS-CoV viral spike cannot bind gangliosides to infect the targeted cells.15 If benefit is confirmed and safety is established, chloroquine may be of added therapeutic value in future patients with COVID-19–triggered GBS in conjunction with IVIg.\n"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T106","span":{"begin":112,"end":117},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"s and, in the presence of chloroquine, the SARS-CoV viral spike cannot bind gangliosides to infect the targeted cells.15 If benefit is confirmed and safety is established, chloroquine may be of added therapeutic value in future patients with COVID-19–triggered GBS in conjunction with IVIg.\n"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T89","span":{"begin":26,"end":37},"obj":"Chemical"},{"id":"T90","span":{"begin":76,"end":88},"obj":"Chemical"},{"id":"T91","span":{"begin":172,"end":183},"obj":"Chemical"}],"attributes":[{"id":"A89","pred":"chebi_id","subj":"T89","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A90","pred":"chebi_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A91","pred":"chebi_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"}],"text":"s and, in the presence of chloroquine, the SARS-CoV viral spike cannot bind gangliosides to infect the targeted cells.15 If benefit is confirmed and safety is established, chloroquine may be of added therapeutic value in future patients with COVID-19–triggered GBS in conjunction with IVIg.\n"}

{"project":"LitCovid-PubTator","denotations":[{"id":"505","span":{"begin":43,"end":51},"obj":"Species"},{"id":"506","span":{"begin":228,"end":236},"obj":"Species"},{"id":"530","span":{"begin":26,"end":37},"obj":"Chemical"},{"id":"531","span":{"begin":76,"end":88},"obj":"Chemical"},{"id":"532","span":{"begin":172,"end":183},"obj":"Chemical"},{"id":"545","span":{"begin":242,"end":250},"obj":"Disease"}],"attributes":[{"id":"A505","pred":"tao:has_database_id","subj":"505","obj":"Tax:694009"},{"id":"A506","pred":"tao:has_database_id","subj":"506","obj":"Tax:9606"},{"id":"A530","pred":"tao:has_database_id","subj":"530","obj":"MESH:D002738"},{"id":"A531","pred":"tao:has_database_id","subj":"531","obj":"MESH:D005732"},{"id":"A532","pred":"tao:has_database_id","subj":"532","obj":"MESH:D002738"},{"id":"A545","pred":"tao:has_database_id","subj":"545","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"s and, in the presence of chloroquine, the SARS-CoV viral spike cannot bind gangliosides to infect the targeted cells.15 If benefit is confirmed and safety is established, chloroquine may be of added therapeutic value in future patients with COVID-19–triggered GBS in conjunction with IVIg.\n"}